Literature DB >> 1384593

The channel-forming toxin aerolysin.

J T Buckley1.   

Abstract

Aeromonas sp. secrete a precursor of the cytolytic protein aerolysin into the culture medium, where it is activated by proteolytic removal of a C-terminal fragment. Activation can be achieved by a variety of mammalian proteases as well as by proteases released by the bacteria itself. Activated toxin binds with high affinity to the transmembrane protein glycophorin on the surface of eucaryotic cells. Binding is followed by oligomerization and the formation of transmembrane channels, leading to cell death. Using chemical modification and site-directed mutagenesis, we have identified regions of the molecule which are important in transfer across the outer membrane of the bacteria, and in proteolytic activation, binding, and oligomerization. A preliminary electron density map of proaerolysin crystals indicates that the protein is organized into three domains. Analysis of two-dimensional crystals of aerolysin suggests that the oligomeric form of the protein is heptameric.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384593     DOI: 10.1111/j.1574-6968.1992.tb05881.x

Source DB:  PubMed          Journal:  FEMS Microbiol Immunol        ISSN: 0920-8534


  3 in total

Review 1.  [Minimally invasive treatment of benign prostatic hyperplasia].

Authors:  G Magistro; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

Review 2.  New intraprostatic injectables and prostatic urethral lift for male LUTS.

Authors:  Giuseppe Magistro; Christian G Stief; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2015-07-21       Impact factor: 14.432

3.  Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer.

Authors:  Oliver C Rogers; Lizamma Antony; Oren Levy; Nitin Joshi; Brian W Simons; Susan L Dalrymple; D Marc Rosen; Andrew Pickering; Haoyue Lan; Heidi Kuang; Sudhir H Ranganath; Lei Zheng; Jeffrey M Karp; S Peter Howard; Samuel R Denmeade; John T Isaacs; W Nathaniel Brennen
Journal:  Mol Cancer Ther       Date:  2020-09-17       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.